ConfavreuxCHutchinsonMHoursMM. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med1998; 339: 285–291.
2.
KarpIManganasASylvestreMP. Does pregnancy alter the long-term course of multiple sclerosis?Ann Epidemiol2014; 24: 504–508.
3.
LuEWangBWGuimondC. Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review. Neurology2012; 79: 1130–1135.
4.
EbrahimiNHerbstrittSGoldR. Pregnancy outcomes following natalizumab exposure. A prospective controlled observational study. Mult Scler2014 [epub ahead of print].
5.
HaghikiaALanger-GouldARellensmannG. Natalizumab use during the third trimester of pregnancy. JAMA Neurol2014; 71: 891–895.
6.
FagiusJBurmanJ. Normal outcome of pregnancy with ongoing treatment with natalizumab. Acta Neurol Scand2014; 129: e27–e29.
7.
SorensenPSKoch-HenriksenNPetersenT. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol2014; 261: 1170–1177.
8.
Salhofer-PolanyiSBaumgartnerAKrausJ. What to expect after natalizumab cessation in a real-life setting. Acta Neurol Scand2014; 130: 97–102.
9.
HavlaJKleiterIKümpfelT. Bridging, switching or drug holidays – how to treat a patient who stops natalizumab?Ther Clin Risk Manag2013; 9: 361–369.
